Immunoglobulin containing Rh(D) antibodies obtained from immunized donors which prevents hemolytic disease of the newborn

 

rhesonativ product information

rhesonativ SPC.pdf

rhesonativ - Preventing heamolytic disease in newborns

Human anti-D immunoglobulin for intramuscular administration for prevention of Rh immunisation in Rh-negative or Rh-partial pregnant women.

 

Treatment of Rh(D)-negative persons after incompatible transfusions Rh(D)-positive. 30-month shelf-life at 2 - 8 °C.

 

Available in vials of:

  • 625 IU (125 μg)
  • 750 IU (150 μg)
  • 1,250 IU / 1,500 IU (250 μg/300 μg)